• For the second consecutive year, it has been included in the Dow Jones Sustainability Index, demonstrating leadership in sustainable development.
• Leading the development of green biopharmaceuticals and empowering a healthy future through technological innovation.

Shanghai, January 2, 2025 /PR Newswire/ -- WUXI BIO (WuXi Biologics, 2269.HK), a global leading contract research, development and manufacturing (CRDMO) services company, announced that due to its relentless efforts and outstanding achievements in promoting sustainable development, the company has been selected for the 2024 Dow Jones Sustainability Index (DJSI) and ranks among the top in the industry.

The DJSI provides investors with a series of authoritative industry benchmarks, confirming the critical importance of creating long-term Shareholder value through sustainable business practices and reflecting investors' concerns and emphasis on sustainability in Asset allocation. This index series was launched in 1999 and is the world's first sustainability benchmark Indicator. Among them, the DJSI World represents assessment Indicators for corporate sustainability as part of the S&P Global broad market index, evaluating the top 2,500 companies globally on environmental, social, and corporate governance dimensions and finally selecting the top 10% of companies in each category.

Dr. Chen Zhisheng, CEO of WUXI BIO and Chairman of the ESG Committee, stated: "We are very honored to have been selected for the DJSI for the second consecutive year. This is not only a reflection of our continuous improvement in sustainable development capabilities but also an acknowledgment of our achievements in sustainability. As a global leader in green biopharmaceutical solutions, we continuously pursue excellence in ESG performance while consistently providing innovative end-to-end solutions for green research and development, green development, and green production to global partners. Looking to the future, we will continue to collaborate with all parties to promote more responsible practices throughout the entire value chain."

In recent years, WUXI BIO's strategies and initiatives in the field of sustainable development have made significant progress and received widespread recognition in the industry. With leading green biopharmaceutical solutions (Green CRDMO), the company successfully made it into the United Nations Global Compact Organization (UNGC) report on "'Twenty Year Top Twenty' Corporate Sustainability Cases." Additionally, the company has received the highest AAA ESG rating from MSCI for two consecutive years; it has been recognized by Morningstar Sustainalytics as an "industry top-rated" and "regional (Asia-Pacific) top-rated" enterprise; it has ranked on the CDP water security "A-list" and obtained a CDP climate change leadership rating of A-; it has been included in the FTSE Social Responsibility Index series; and it has been included in the Hang Seng ESG 50 Index, fully demonstrating the company's outstanding performance in the field of sustainable development.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global open-access biologics technology platform offering end-to-end solutions to empower and accelerate biologics discovery, development, and manufacturing. The company's services are designed to help its partners achieve their goals at all stages of the biologics life cycle, from concept to commercial manufacturing. WuXi Biologics' innovative platforms and solution-focused services are designed to help customers bring innovative biologics products to market faster and more efficiently, ultimately benefiting patients worldwide.

Wuxi Bio has over 12,000 employees in China, the USA, Ireland, Germany, and Singapore. Through Wuxi Bio's professional services team, as well as advanced technology and deep insights, the company provides customers with efficient and cost-effective solutions for biopharmaceuticals. As of the end of June 2024, Wuxi Bio has assisted customers in developing and producing a total of 742 comprehensive projects, including 16 commercial production projects (excluding new crown projects and inactive projects).

WUXI BIO considers Environmental, Social and Governance (ESG) as an important part of business development and corporate spirit, and is committed to becoming the global leader in ESG in the biopharmaceutical CRDMO field, such as applying greener new-generation biopharmaceutical technologies and Energy to lead Industry development. The company has established an ESG committee led by the CEO to fully implement the ESG strategy and practice its commitment to sustainable development. For more information, please visit:

Media Relations
PR@wuxibiologics.com

ESG
esg@wuxibiologics.com